Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Influenza

Free Subscription Articles published in Antiviral Res Retrieve available abstracts of 164 articles: HTML format

Single Articles

September 2023
1. GAO R, Pascua PNQ, Nguyen HT, Chesnokov A, et al
   New insights into the neuraminidase-mediated hemagglutination activity of influenza A(H3N2) viruses.
   Antiviral Res. 2023;218:105719.
   PubMed     Abstract available
   
   
   August 2023
2. IVASHCHENKO AA, Jones JC, Shkil DO, Ivanenkov YA, et al
   Resistance profiles for the investigational neuraminidase inhibitor AV5080 in influenza A and B viruses.
   Antiviral Res. 2023;217:105701.
   PubMed     Abstract available
   
   
   
3. VANDERLINDEN E, Boonen A, Noppen S, Schoofs G, et al
   PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding.
   Antiviral Res. 2023;217:105700.
   PubMed     Abstract available
   
   
   
4. CORONA A, Madia VN, De Santis R, Manelfi C, et al
   Diketo acid inhibitors of nsp13 of SARS-CoV-2 block viral replication.
   Antiviral Res. 2023;217:105697.
   PubMed     Abstract available
   
   
   July 2023
5. NGUYEN HT, Chesnokov A, De La Cruz J, Pascua PNQ, et al
   Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022.
   Antiviral Res. 2023 Jul 24:105679. doi: 10.1016/j.antiviral.2023.105679.
   PubMed     Abstract available
   
   
   
6. SPENGLER JR, Carter K, Delang L, Durantel D, et al
   Meeting report: 36th international conference on antiviral research in Lyon, France, March 13-17, 2023.
   Antiviral Res. 2023 Jul 24:105678. doi: 10.1016/j.antiviral.2023.105678.
   PubMed     Abstract available
   
   
   
7. SUPREWICZ L, Szczepanski A, Lenart M, Piktel E, et al
   Ceragenins exhibit antiviral activity against SARS-CoV-2 by increasing the expression and release of type I interferons upon activation of the host's immune response.
   Antiviral Res. 2023 Jul 20:105676. doi: 10.1016/j.antiviral.2023.105676.
   PubMed     Abstract available
   
   
   
8. BOWDEN-REID E, Ledger S, Zhang Y, Di Giallonardo F, et al
   Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2.
   Antiviral Res. 2023 Jul 19:105677. doi: 10.1016/j.antiviral.2023.105677.
   PubMed     Abstract available
   
   
   
9. TAKASHITA E, Fujisaki S, Morita H, Nagata S, et al
   Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors.
   Antiviral Res. 2023;216:105671.
   PubMed     Abstract available
   
   
   
10. JEONG JH, Choi JH, Kim BK, Min SC, et al
    Evaluating Z-FA-FMK, a host cathepsin L protease inhibitor, as a potent and broad-spectrum antiviral therapy against SARS-CoV-2 and related coronaviruses.
    Antiviral Res. 2023 Jul 10:105669. doi: 10.1016/j.antiviral.2023.105669.
    PubMed     Abstract available
    
    
    
11. FENG Y, Yang Y, Zou S, Qiu S, et al
    Identification of alpha-linolenic acid as a broad-spectrum antiviral against zika, dengue, herpes simplex, influenza virus and SARS-CoV-2 infection.
    Antiviral Res. 2023 Jul 8:105666. doi: 10.1016/j.antiviral.2023.105666.
    PubMed     Abstract available
    
    
    June 2023
12. MU S, Zou X, Wang Y, Deng X, et al
    The combined effect of oseltamivir and favipiravir on influenza a virus evolution in patients hospitalized with severe influenza.
    Antiviral Res. 2023 Jun 25:105657. doi: 10.1016/j.antiviral.2023.105657.
    PubMed     Abstract available
    
    
    
13. CAI H, Yan J, Liu S, Li P, et al
    Paxlovid for hospitalized COVID-19 patients with chronic kidney disease.
    Antiviral Res. 2023 Jun 25:105659. doi: 10.1016/j.antiviral.2023.105659.
    PubMed     Abstract available
    
    
    
14. MILAN BONOTTO R, Mitrovic A, Sosic I, Martinez-Orellana P, et al
    Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection.
    Antiviral Res. 2023;216:105655.
    PubMed     Abstract available
    
    
    
15. JUNG HE, Ku KB, Kang BH, Park JH, et al
    Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2.
    Antiviral Res. 2023;216:105656.
    PubMed     Abstract available
    
    
    
16. CHANG YJ, Le UNP, Liu JJ, Li SR, et al
    Combining virtual screening with cis-/trans-cleavage enzymatic assays effectively reveals broad-spectrum inhibitors that target the main proteases of SARS-CoV-2 and MERS-CoV.
    Antiviral Res. 2023 Jun 13:105653. doi: 10.1016/j.antiviral.2023.105653.
    PubMed     Abstract available
    
    
    
17. ZHANG J, Nian X, Liu B, Zhang Z, et al
    Development of MDCK-based quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection: A preclinical study.
    Antiviral Res. 2023;216:105639.
    PubMed     Abstract available
    
    
    May 2023
18. WU CY, Kao SE, Tseng YC, Lin YP, et al
    Pilot-scale production of inactivated monoglycosylated split H(1)N(1) influenza virus vaccine provides cross-strain protection against influenza viruses.
    Antiviral Res. 2023 May 30:105640. doi: 10.1016/j.antiviral.2023.105640.
    PubMed     Abstract available
    
    
    
19. WANG X, Lin L, Chen Z, Si W, et al
    Mutations at site 207 of influenza a virus NS1 protein switch its function in regulating RIG-I-like receptors mediated antiviral responses.
    Antiviral Res. 2023 May 23:105641. doi: 10.1016/j.antiviral.2023.105641.
    PubMed     Abstract available
    
    
    
20. DRIOUICH JS, Bernadin O, Touret F, de Lamballerie X, et al
    Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model.
    Antiviral Res. 2023 May 17:105638. doi: 10.1016/j.antiviral.2023.105638.
    PubMed     Abstract available
    
    
    
21. HUANG X, Fan W, Sun J, Yang J, et al
    SARS-CoV-2 induces cardiomyocyte apoptosis and inflammation but can be ameliorated by ACE inhibitor Captopril.
    Antiviral Res. 2023 May 17:105636. doi: 10.1016/j.antiviral.2023.105636.
    PubMed     Abstract available
    
    
    
22. HU J, Zhang L, Zheng X, Wang G, et al
    Long noncoding RNA #61 exerts a broad anti-influenza a virus effect by its long arm rings.
    Antiviral Res. 2023 May 15:105637. doi: 10.1016/j.antiviral.2023.105637.
    PubMed     Abstract available
    
    
    
23. YANG X, Long F, Jia W, Zhang M, et al
    Artesunate inhibits PDE4 leading to intracellular cAMP accumulation, reduced ERK/MAPK signaling, and blockade of influenza A virus vRNP nuclear export.
    Antiviral Res. 2023 May 14:105635. doi: 10.1016/j.antiviral.2023.105635.
    PubMed     Abstract available
    
    
    April 2023
24. CHO J, Shin Y, Yang JS, Kim JW, et al
    Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants.
    Antiviral Res. 2023;214:105609.
    PubMed     Abstract available
    
    
    
25. LI Y, Wang K, Sun H, Wu S, et al
    Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2.
    Antiviral Res. 2023 Apr 17:105606. doi: 10.1016/j.antiviral.2023.105606.
    PubMed     Abstract available
    
    
    
26. CONG Y, Lee JH, Perry DL, Cooper K, et al
    Longitudinal analyses using (18)F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster models.
    Antiviral Res. 2023 Apr 15:105605. doi: 10.1016/j.antiviral.2023.105605.
    PubMed     Abstract available
    
    
    March 2023
27. SON S, Ahn SB, Kim G, Jang Y, et al
    Identification of broad-spectrum neutralizing antibodies against influenza A virus and evaluation of their prophylactic efficacy in mice.
    Antiviral Res. 2023;213:105591.
    PubMed     Abstract available
    
    
    
28. BILLS C, Xie X, Shi PY
    The multiple roles of nsp6 in the molecular pathogenesis of SARS-CoV-2.
    Antiviral Res. 2023;213:105590.
    PubMed     Abstract available
    
    
    
29. CONG Y, Mucker EM, Perry DL, Dixit S, et al
    Evaluation of a panel of therapeutic antibody clinical candidates for efficacy against SARS-CoV-2 in Syrian hamsters.
    Antiviral Res. 2023;213:105589.
    PubMed     Abstract available
    
    
    
30. YANG Y, Cao L, Yan M, Zhou J, et al
    Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2.
    Antiviral Res. 2023 Mar 28:105586. doi: 10.1016/j.antiviral.2023.105586.
    PubMed     Abstract available
    
    
    
31. VANHULLE E, Doijen J, Stroobants J, Provinciael B, et al
    Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic potential of spike mutants.
    Antiviral Res. 2023;213:105587.
    PubMed     Abstract available
    
    
    
32. DICHTL S, Diem G, Jager M, Zaderer V, et al
    Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to reduce tissue inflammation.
    Antiviral Res. 2023 Mar 23:105581. doi: 10.1016/j.antiviral.2023.105581.
    PubMed     Abstract available
    
    
    
33. ALVES RPDS, Wang YT, Mikulski Z, McArdle S, et al
    SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model.
    Antiviral Res. 2023 Mar 18:105580. doi: 10.1016/j.antiviral.2023.105580.
    PubMed     Abstract available
    
    
    
34. LU C, Zhang Y, Liu X, Hou F, et al
    Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine.
    Antiviral Res. 2023;212:105556.
    PubMed     Abstract available
    
    
    
35. KIM JW, Heo K, Kim HJ, Yoo Y, et al
    Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants.
    Antiviral Res. 2023;212:105576.
    PubMed     Abstract available
    
    
    
36. SHEKUNOV EV, Zlodeeva PD, Efimova SS, Muryleva AA, et al
    Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks for old dogs.
    Antiviral Res. 2023;212:105575.
    PubMed     Abstract available
    
    
    
37. ISSMAIL L, Ramsbeck D, Jager C, Henning T, et al
    Identification and evaluation of a novel tribenzamide derivative as an inhibitor targeting the entry of the respiratory syncytial virus.
    Antiviral Res. 2023;211:105547.
    PubMed     Abstract available
    
    
    
38. HU Y, Zhu Y, Yu Y, Liu N, et al
    Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides.
    Antiviral Res. 2023;212:105571.
    PubMed     Abstract available
    
    
    February 2023
39. XIAO Y, Yan Y, Chang L, Ji H, et al
    CDK4/6 inhibitor palbociclib promotes SARS-CoV-2 cell entry by down-regulating SKP2 dependent ACE2 degradation.
    Antiviral Res. 2023 Feb 18:105558. doi: 10.1016/j.antiviral.2023.105558.
    PubMed     Abstract available
    
    
    
40. LI J, Wang Y, Solanki K, Atre R, et al
    Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses.
    Antiviral Res. 2023 Feb 13:105555. doi: 10.1016/j.antiviral.2023.105555.
    PubMed     Abstract available
    
    
    
41. MERINO VF, Yan Y, Ordonez AA, Bullen CK, et al
    Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells.
    Antiviral Res. 2023;211:105550.
    PubMed     Abstract available
    
    
    
42. KURHADE C, Xie X, Shi PY
    Reverse genetic systems of SARS-CoV-2 for antiviral research.
    Antiviral Res. 2023;210:105486.
    PubMed     Abstract available
    
    
    January 2023
43. ZHU Y, Li M, Liu N, Wu T, et al
    Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2.
    Antiviral Res. 2023;211:105541.
    PubMed     Abstract available
    
    
    
44. BASILE A, Zannella C, De Marco M, Sanna G, et al
    Spike-mediated viral membrane fusion is inhibited by a specific anti-IFITM2 monoclonal antibody.
    Antiviral Res. 2023;211:105546.
    PubMed     Abstract available
    
    
    
45. HU L, Lao G, Liu R, Feng J, et al
    Corrigendum to "The race toward a universal influenza vaccine: Front runners and the future directions" [Antivir. Res. (2022) 105505].
    Antiviral Res. 2023 Jan 15:105543. doi: 10.1016/j.antiviral.2023.105543.
    PubMed    
    
    
    December 2022
46. SPENGLER JR, Welch SR, Deval J, Gentry BG, et al
    Meeting report: 35th international conference on antiviral research in Seattle, WA, USA - March 21-25, 2022.
    Antiviral Res. 2022 Dec 31:105521. doi: 10.1016/j.antiviral.2022.105521.
    PubMed     Abstract available
    
    
    
47. CHISTOV AA, Chumakov SP, Mikhnovets IE, Nikitin TD, et al
    5-(Perylen-3-ylethynyl)uracil as an antiviral scaffold: Potent suppression of enveloped virus reproduction by 3-methyl derivatives in vitro.
    Antiviral Res. 2022 Dec 26:105508. doi: 10.1016/j.antiviral.2022.105508.
    PubMed     Abstract available
    
    
    
48. LIM SP
    Targeting SARS-CoV-2 and host cell receptor interactions.
    Antiviral Res. 2022 Dec 26:105514. doi: 10.1016/j.antiviral.2022.105514.
    PubMed     Abstract available
    
    
    
49. HU L, Lao G, Liu R, Feng J, et al
    The race toward a universal influenza vaccine: Front runners and the future directions.
    Antiviral Res. 2022 Dec 24:105505. doi: 10.1016/j.antiviral.2022.105505.
    PubMed     Abstract available
    
    
    
50. HU L, Tang Y, Mei L, Liang M, et al
    A new intracellular targeting motif in the cytoplasmic tail of the spike protein may act as a target to inhibit SARS-CoV-2 assembly.
    Antiviral Res. 2022;209:105509.
    PubMed     Abstract available
    
    
    
51. JONES JC, Yen HL, Adams P, Armstrong K, et al
    Influenza antivirals and their role in pandemic preparedness.
    Antiviral Res. 2022 Dec 23:105499. doi: 10.1016/j.antiviral.2022.105499.
    PubMed     Abstract available
    
    
    
52. TNG DJH, Low JGH
    Current status of silica-based nanoparticles as therapeutics and its potential as therapies against viruses.
    Antiviral Res. 2022 Dec 22:105488. doi: 10.1016/j.antiviral.2022.105488.
    PubMed     Abstract available
    
    
    
53. ZHANG YN, Zhang HQ, Wang GF, Zhang ZR, et al
    Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster.
    Antiviral Res. 2022;209:105507.
    PubMed     Abstract available
    
    
    
54. SHANNON A, Canard B
    Kill or corrupt: Mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2.
    Antiviral Res. 2022 Dec 21:105501. doi: 10.1016/j.antiviral.2022.105501.
    PubMed     Abstract available
    
    
    
55. CHIU W, Schepers J, Francken T, Vangeel L, et al
    Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery.
    Antiviral Res. 2022 Dec 21:105506. doi: 10.1016/j.antiviral.2022.105506.
    PubMed     Abstract available
    
    
    
56. TANG Y, Su R, Gu Q, Hu Y, et al
    PI3K/AKT-mediated autophagy inhibition facilitates mast cell activation to enhance severe inflammatory lung injury in influenza A virus- and secondary Staphylococcus aureus-infected mice.
    Antiviral Res. 2022 Dec 19:105502. doi: 10.1016/j.antiviral.2022.105502.
    PubMed     Abstract available
    
    
    
57. JOHNSON DM, Brasel T, Massey S, Garron T, et al
    Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model.
    Antiviral Res. 2022 Dec 16:105492. doi: 10.1016/j.antiviral.2022.105492.
    PubMed     Abstract available
    
    
    
58. PEREZ-VARGAS J, Shapira T, Olmstead AD, Villanueva I, et al
    Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics.
    Antiviral Res. 2022 Dec 8:105484. doi: 10.1016/j.antiviral.2022.105484.
    PubMed     Abstract available
    
    
    
59. HASHIZUME M, Takashima A, Ono C, Okamoto T, et al
    Phenothiazines inhibit SARS-CoV-2 cell entry via a blockade of spike protein binding to neuropilin-1.
    Antiviral Res. 2022 Dec 5:105481. doi: 10.1016/j.antiviral.2022.105481.
    PubMed     Abstract available
    
    
    
60. YAO Y, Sun H, Chen Y, Tian L, et al
    RBM24 inhibits the translation of SARS-CoV-2 polyproteins by targeting the 5'-untranslated region.
    Antiviral Res. 2022;209:105478.
    PubMed     Abstract available
    
    
    November 2022
61. JEONG K, Chang J, Park SM, Kim J, et al
    Rapid discovery and classification of inhibitors of coronavirus infection by pseudovirus screen and amplified luminescence proximity homogeneous assay.
    Antiviral Res. 2022 Nov 23:105473. doi: 10.1016/j.antiviral.2022.105473.
    PubMed     Abstract available
    
    
    
62. FAIST A, Schloer S, Mecate-Zambrano A, Janowski J, et al
    Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier.
    Antiviral Res. 2022 Nov 21:105475. doi: 10.1016/j.antiviral.2022.105475.
    PubMed     Abstract available
    
    
    
63. HUI X, Yu X, Huang K, Xu T, et al
    In vitro and in vivo effects of 3-indoleacetonitrile-A potential new broad-spectrum therapeutic agent for SARS-CoV-2 infection.
    Antiviral Res. 2022 Nov 16:105465. doi: 10.1016/j.antiviral.2022.105465.
    PubMed     Abstract available
    
    
    
64. YANG F, Yan S, Zhu L, Wang FXC, et al
    Evaluation of panel of neutralising murine monoclonal antibodies and a humanised bispecific antibody against influenza A(H1N1)pdm09 virus infection in a mouse model.
    Antiviral Res. 2022 Nov 14:105462. doi: 10.1016/j.antiviral.2022.105462.
    PubMed     Abstract available
    
    
    
65. FABREGA-FERRER M, Herrera-Morande A, Muriel-Goni S, Perez-Saavedra J, et al
    Structure and inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases by oral antiviral compound AG7404.
    Antiviral Res. 2022;208:105458.
    PubMed     Abstract available
    
    
    
66. PATEL MC, Flanigan D, Feng C, Chesnokov A, et al
    An optimized cell-based assay to assess influenza virus replication by measuring neuraminidase activity and its applications for virological surveillance.
    Antiviral Res. 2022 Nov 1:105457. doi: 10.1016/j.antiviral.2022.105457.
    PubMed     Abstract available
    
    
    October 2022
67. PASCUA PNQ, Jones JC, Webby RJ, Govorkova EA, et al
    Effect of E23G/K, F36V, N37T, E119D, and E199G polymerase acidic protein substitutions on the replication and baloxavir susceptibility of influenza B viruses.
    Antiviral Res. 2022 Oct 31:105455. doi: 10.1016/j.antiviral.2022.105455.
    PubMed     Abstract available
    
    
    
68. SHANG W, Dai W, Yao C, Xu L, et al
    In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2.
    Antiviral Res. 2022;208:105450.
    PubMed     Abstract available
    
    
    
69. VARRICCHIO C, Mathez G, Pillonel T, Bertelli C, et al
    Geneticin shows selective antiviral activity against SARS-CoV-2 by interfering with programmed -1 ribosomal frameshifting.
    Antiviral Res. 2022;208:105452.
    PubMed     Abstract available
    
    
    
70. RADILOVA K, Zima V, Kral M, Machara A, et al
    Thermodynamic and structural characterization of an optimized peptide-based inhibitor of the influenza polymerase PA-PB1 subunit interaction.
    Antiviral Res. 2022 Oct 17:105449. doi: 10.1016/j.antiviral.2022.105449.
    PubMed     Abstract available
    
    
    
71. ZHU Y, Hu Y, Liu N, Chong H, et al
    Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides.
    Antiviral Res. 2022;208:105445.
    PubMed     Abstract available
    
    
    
72. KIM TY, Kim JY, Kwon HC, Jeon S, et al
    Astersaponin I from Aster koraiensis is a natural viral fusion blocker that inhibit the infection of SARS-CoV-2 variants and syncytium formation.
    Antiviral Res. 2022 Oct 14:105428. doi: 10.1016/j.antiviral.2022.105428.
    PubMed     Abstract available
    
    
    
73. BRAY M
    Antiviral Research: At age 41, a transition.
    Antiviral Res. 2022 Oct 14:105447. doi: 10.1016/j.antiviral.2022.105447.
    PubMed     Abstract available
    
    
    
74. JEONG JH, Chokkakula S, Min SC, Kim BK, et al
    Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice.
    Antiviral Res. 2022;208:105430.
    PubMed     Abstract available
    
    
    
75. ZHU Y, Binder J, Yurgelonis I, Rai D, et al
    Generation of a VeroE6 Pgp gene knock out cell line and its use in SARS-CoV-2 antiviral study.
    Antiviral Res. 2022 Oct 5:105429. doi: 10.1016/j.antiviral.2022.105429.
    PubMed     Abstract available
    
    
    September 2022
76. MA L, Li Q, Xie Y, Jianyuan Zhao, et al
    Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL(pro).
    Antiviral Res. 2022 Sep 22:105419. doi: 10.1016/j.antiviral.2022.105419.
    PubMed     Abstract available
    
    
    
77. CHENG Y, Yang C, Li Z, Li X, et al
    Anti-influenza virus activity of the REV-ERBalpha agonist SR9009 and related analogues.
    Antiviral Res. 2022 Sep 16:105418. doi: 10.1016/j.antiviral.2022.105418.
    PubMed     Abstract available
    
    
    August 2022
78. DEMAREST JF, Kienle M, Boytz R, Ayres M, et al
    Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19.
    Antiviral Res. 2022 Aug 27:105403. doi: 10.1016/j.antiviral.2022.105403.
    PubMed     Abstract available
    
    
    
79. LU L, Peng Y, Yao H, Wang Y, et al
    Punicalagin as an allosteric NSP13 helicase inhibitor potently suppresses SARS-CoV-2 replication in vitro.
    Antiviral Res. 2022 Aug 16:105389. doi: 10.1016/j.antiviral.2022.105389.
    PubMed     Abstract available
    
    
    
80. KOMENO T, Furuta Y, Nakajima N, Tani H, et al
    Analysis of the responsible site for favipiravir resistance in RNA-dependent RNA polymerase of influenza virus A/PR/8/34 (H1N1) using site-directed mutagenesis.
    Antiviral Res. 2022 Aug 2:105387. doi: 10.1016/j.antiviral.2022.105387.
    PubMed     Abstract available
    
    
    
81. CIVRA A, Costantino M, Cavalli R, Adami M, et al
    27-Hydroxycholesterol inhibits rhinovirus replication in vitro and on human nasal and bronchial histocultures without selecting viral resistant variants.
    Antiviral Res. 2022;204:105368.
    PubMed     Abstract available
    
    
    July 2022
82. LI M, Chen J, Liu Y, Zhao J, et al
    Rational design of AAVrh10-vectored ACE2 functional domain to broadly block the cell entry of SARS-CoV-2 variants.
    Antiviral Res. 2022 Jul 30:105383. doi: 10.1016/j.antiviral.2022.105383.
    PubMed     Abstract available
    
    
    
83. SAMRAT SK, Xu J, Xie X, Gianti E, et al
    Allosteric inhibitors of the main protease of SARS-CoV-2.
    Antiviral Res. 2022;205:105381.
    PubMed     Abstract available
    
    
    
84. BEZERRA BB, Silva GPDD, Antunes Coelho SV, Correa IA, et al
    Hydroxypropyl-beta-cyclodextrin (HP-BCD) inhibits SARS-CoV-2 replication and virus-induced inflammatory cytokines.
    Antiviral Res. 2022 Jul 4:105373. doi: 10.1016/j.antiviral.2022.105373.
    PubMed     Abstract available
    
    
    
85. OHASHI H, Hishiki T, Akazawa D, Kim KS, et al
    Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.
    Antiviral Res. 2022 Jul 4:105372. doi: 10.1016/j.antiviral.2022.105372.
    PubMed     Abstract available
    
    
    June 2022
86. KIM EH, Lee BW, Ryu B, Cho HM, et al
    Inhibition of a broad range of SARS-CoV-2 variants by antiviral phytochemicals in hACE2 mice.
    Antiviral Res. 2022;204:105371.
    PubMed     Abstract available
    
    
    
87. SEEPHETDEE C, Bhukhai K, Buasri N, Leelukkanaveera P, et al
    A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera.
    Antiviral Res. 2022 Jun 27:105370. doi: 10.1016/j.antiviral.2022.105370.
    PubMed     Abstract available
    
    
    
88. JONES JC, Rovito SW, Penaflor MK, Webby RJ, et al
    Influenza A virus polymerase acidic protein E23R substitution is a marker of reduced susceptibility to baloxavir.
    Antiviral Res. 2022 Jun 20:105369. doi: 10.1016/j.antiviral.2022.105369.
    PubMed     Abstract available
    
    
    
89. KARIM M, Saul S, Ghita L, Sahoo MK, et al
    Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for antiviral strategies.
    Antiviral Res. 2022 Jun 20:105367. doi: 10.1016/j.antiviral.2022.105367.
    PubMed     Abstract available
    
    
    
90. ZHOU M, Liu Y, Cao J, Dong S, et al
    Bergamottin, a bioactive component of bergamot, inhibits SARS-CoV-2 infection in golden Syrian hamsters.
    Antiviral Res. 2022 Jun 19:105365. doi: 10.1016/j.antiviral.2022.105365.
    PubMed     Abstract available
    
    
    
91. HERNANDEZ S, Feracci M, De Jesus CT, El Kazzi P, et al
    Identification of potent inhibitors of arenavirus and SARS-CoV-2 exoribonucleases by fluorescence polarization assay.
    Antiviral Res. 2022 Jun 15:105364. doi: 10.1016/j.antiviral.2022.105364.
    PubMed     Abstract available
    
    
    
92. MELO-FILHO CC, Bobrowski T, Martin HJ, Sessions Z, et al
    Conserved coronavirus proteins as targets of broad-spectrum antivirals.
    Antiviral Res. 2022 Jun 9:105360. doi: 10.1016/j.antiviral.2022.105360.
    PubMed     Abstract available
    
    
    
93. MERCORELLI B, Desantis J, Celegato M, Bazzacco A, et al
    Discovery of novel SARS-CoV-2 inhibitors targeting the main protease M(pro) by virtual screenings and hit optimization.
    Antiviral Res. 2022;204:105350.
    PubMed     Abstract available
    
    
    May 2022
94. PRASHAR P, Swain S, Adhikari N, Aryan P, et al
    A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies.
    Antiviral Res. 2022 May 28:105349. doi: 10.1016/j.antiviral.2022.105349.
    PubMed     Abstract available
    
    
    
95. LIN Q, Lu C, Hong Y, Li R, et al
    Animal models for studying coronavirus infections and developing antiviral agents and vaccines.
    Antiviral Res. 2022 May 20:105345. doi: 10.1016/j.antiviral.2022.105345.
    PubMed     Abstract available
    
    
    
96. ROY A, Alhammad YM, McDonald P, Johnson DK, et al
    Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening.
    Antiviral Res. 2022 May 19:105344. doi: 10.1016/j.antiviral.2022.105344.
    PubMed     Abstract available
    
    
    
97. WEIL T, Lawrenz J, Seidel A, Munch J, et al
    Immunodetection assays for the quantification of seasonal common cold coronaviruses OC43, NL63, or 229E infection confirm nirmatrelvir as broad coronavirus inhibitor.
    Antiviral Res. 2022 May 19:105343. doi: 10.1016/j.antiviral.2022.105343.
    PubMed     Abstract available
    
    
    
98. VANHULLE E, Stroobants J, Provinciael B, Camps A, et al
    SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening.
    Antiviral Res. 2022 May 17:105342. doi: 10.1016/j.antiviral.2022.105342.
    PubMed     Abstract available
    
    
    
99. FINDLAY-WILSON S, Easterbrook L, Smith S, Pope N, et al
    Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins.
    Antiviral Res. 2022 May 6:105332. doi: 10.1016/j.antiviral.2022.105332.
    PubMed     Abstract available
    
    
    
100. PITTS J, Babusis D, Vermillion MS, Subramanian R, et al
     Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection.
     Antiviral Res. 2022 May 4:105329. doi: 10.1016/j.antiviral.2022.105329.
     PubMed     Abstract available
     
     
     
101. ZHAO L, Yan Y, Dai Q, Wang Z, et al
     The CDK1 inhibitor, Ro-3306, is a potential antiviral candidate against influenza virus infection.
     Antiviral Res. 2022;201:105296.
     PubMed     Abstract available
     
     
     April 2022
102. FOO CS, Abdelnabi R, Kaptein SJF, Zhang X, et al
     HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect.
     Antiviral Res. 2022;202:105311.
     PubMed     Abstract available
     
     
     
103. VANMECHELEN B, Stroobants J, Chiu W, Schepers J, et al
     Identification of novel Ebola virus inhibitors using biologically contained virus.
     Antiviral Res. 2022;200:105294.
     PubMed     Abstract available
     
     
     March 2022
104. WAGATSUMA K, Saito R, Chon I, Phyu WW, et al
     Duration of fever and symptoms in influenza-infected children treated with baloxavir marboxil during the 2019-2020 season in Japan and detection of influenza virus with the PA E23K substitution.
     Antiviral Res. 2022;201:105310.
     PubMed     Abstract available
     
     
     
105. HUANG J, Liu X, Sun Y, Huang C, et al
     Porcine beta-defensin 2 confers enhanced resistance to swine flu infection in transgenic pigs and alleviates swine influenza virus-induced apoptosis possibly through interacting with host SLC25A4.
     Antiviral Res. 2022;201:105292.
     PubMed     Abstract available
     
     
     
106. UENO M, Iwata-Yoshikawa N, Matsunaga A, Okamura T, et al
     Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.
     Antiviral Res. 2022;201:105297.
     PubMed     Abstract available
     
     
     
107. BROWN SK, Tseng YY, Aziz A, Baz M, et al
     Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors.
     Antiviral Res. 2022;200:105280.
     PubMed     Abstract available
     
     
     
108. LAI GC, Chao TL, Lin SY, Kao HC, et al
     Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain.
     Antiviral Res. 2022;200:105290.
     PubMed     Abstract available
     
     
     
109. GOVORKOVA EA, Takashita E, Daniels RS, Fujisaki S, et al
     Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020.
     Antiviral Res. 2022 Mar 12:105281. doi: 10.1016/j.antiviral.2022.105281.
     PubMed     Abstract available
     
     
     
110. PASQUERO S, Gugliesi F, Griffante G, Dell'Oste V, et al
     Novel antiviral activity of PAD inhibitors against human beta-coronaviruses HCoV-OC43 and SARS-CoV-2.
     Antiviral Res. 2022;200:105278.
     PubMed     Abstract available
     
     
     
111. SCHOLLE MD, O'Kane PT, Dib S, Gurard-Levin ZA, et al
     Label-free duplex SAMDI-MS screen reveals novel SARS-CoV-2 3CLpro inhibitors.
     Antiviral Res. 2022;200:105279.
     PubMed     Abstract available
     
     
     
112. CHEN KY, Krischuns T, Varga LO, Harigua-Souiai E, et al
     A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors.
     Antiviral Res. 2022 Mar 9:105272. doi: 10.1016/j.antiviral.2022.105272.
     PubMed     Abstract available
     
     
     
113. TANAKA T, Saito A, Suzuki T, Miyamoto Y, et al
     Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening.
     Antiviral Res. 2022;199:105268.
     PubMed     Abstract available
     
     
     February 2022
114. TSAI TI, Khalili JS, Gilchrist M, Waight AB, et al
     ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern.
     Antiviral Res. 2022 Feb 28:105271. doi: 10.1016/j.antiviral.2022.105271.
     PubMed     Abstract available
     
     
     
115. SACHSE M, Tenorio R, Fernandez de Castro I, Munoz-Basagoiti J, et al
     Unraveling the antiviral activity of plitidepsin by subcellular and morphological analysis.
     Antiviral Res. 2022 Feb 26:105270. doi: 10.1016/j.antiviral.2022.105270.
     PubMed     Abstract available
     
     
     January 2022
116. ZHAO J, Liu Q, Yi D, Li Q, et al
     5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis.
     Antiviral Res. 2022 Jan 28:105254. doi: 10.1016/j.antiviral.2022.105254.
     PubMed     Abstract available
     
     
     
117. VANGEEL L, Chiu W, De Jonghe S, Maes P, et al
     Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
     Antiviral Res. 2022 Jan 24:105252. doi: 10.1016/j.antiviral.2022.105252.
     PubMed     Abstract available
     
     
     
118. ABDELNABI R, Foo CS, Zhang X, Lemmens V, et al
     The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters.
     Antiviral Res. 2022 Jan 20:105253. doi: 10.1016/j.antiviral.2022.105253.
     PubMed     Abstract available
     
     
     
119. FOCOSI D, Maggi F, McConnell S, Casadevall A, et al
     Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis.
     Antiviral Res. 2022;198:105247.
     PubMed     Abstract available
     
     
     
120. WILLIAMSON BN, Perez-Perez L, Schwarz B, Feldmann F, et al
     Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2.
     Antiviral Res. 2022 Jan 12:105246. doi: 10.1016/j.antiviral.2022.105246.
     PubMed     Abstract available
     
     
     December 2021
121. MCKIMM-BRESCHKIN JL, Hay AJ, Cao B, Cox RJ, et al
     COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment - Meeting report from an isirv-WHO virtual conference.
     Antiviral Res. 2021 Dec 18:105227. doi: 10.1016/j.antiviral.2021.105227.
     PubMed     Abstract available
     
     
     
122. BHATNAGAR N, Kim KH, Subbiah J, Park BR, et al
     Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice.
     Antiviral Res. 2021 Dec 18:105229. doi: 10.1016/j.antiviral.2021.105229.
     PubMed     Abstract available
     
     
     November 2021
123. COCHIN M, Touret F, Driouich JS, Moureau G, et al
     Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model.
     Antiviral Res. 2021;197:105212.
     PubMed     Abstract available
     
     
     
124. ZHAO J, Zhang G, Zhang Y, Yi D, et al
     2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors.
     Antiviral Res. 2021;196:105209.
     PubMed     Abstract available
     
     
     
125. VANDERLINDEN E, Marchand A, Van Berwaer R, van Dam W, et al
     A broad influenza virus inhibitor acting via IMP dehydrogenase and in synergism with ribavirin.
     Antiviral Res. 2021 Nov 15:105208. doi: 10.1016/j.antiviral.2021.105208.
     PubMed     Abstract available
     
     
     
126. SVILENOV HL, Sacherl J, Reiter A, Wolff LS, et al
     Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein.
     Antiviral Res. 2021 Nov 10:105197. doi: 10.1016/j.antiviral.2021.105197.
     PubMed     Abstract available
     
     
     
127. QIU H, Yuan XY, Cabral T, Manguiat K, et al
     Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies.
     Antiviral Res. 2021 Nov 8:105206. doi: 10.1016/j.antiviral.2021.105206.
     PubMed     Abstract available
     
     
     August 2021
128. GARCIA-DORIVAL I, Cuesta-Geijo MA, Barrado-Gil L, Galindo I, et al
     Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target.
     Antiviral Res. 2021 Aug 24:105167. doi: 10.1016/j.antiviral.2021.105167.
     PubMed     Abstract available
     
     
     
129. ESCAFFRE O, Freiberg AN
     Polyphenylene carboxymethylene (PPCM) microbicide repurposed as antiviral against SARS-CoV-2. Proof of concept in primary human undifferentiated epithelial cells.
     Antiviral Res. 2021 Aug 9:105162. doi: 10.1016/j.antiviral.2021.105162.
     PubMed     Abstract available
     
     
     
130. LEACH A, Ilca FT, Akbar Z, Ferrari M, et al
     A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency.
     Antiviral Res. 2021 Aug 7:105147. doi: 10.1016/j.antiviral.2021.105147.
     PubMed     Abstract available
     
     
     
131. ISON MG, Hayden FG, Hay AJ, Gubareva LV, et al
     Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.
     Antiviral Res. 2021;194:105158.
     PubMed     Abstract available
     
     
     July 2021
132. KASPRZYK R, Spiewla TJ, Smietanski M, Golojuch S, et al
     Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase.
     Antiviral Res. 2021;193:105142.
     PubMed     Abstract available
     
     
     
133. TOURET F, Driouich JS, Cochin M, Petit PR, et al
     Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.
     Antiviral Res. 2021;193:105137.
     PubMed     Abstract available
     
     
     
134. GAN ES, Syenina A, Linster M, Ng B, et al
     A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infection.
     Antiviral Res. 2021;193:105138.
     PubMed     Abstract available
     
     
     
135. PARK JH, Kim B, Antigua KJC, Jeong JH, et al
     Baloxavir-oseltamivir combination therapy inhibits the emergence of resistant substitutions in influenza A virus PA gene in a mouse model.
     Antiviral Res. 2021;193:105126.
     PubMed     Abstract available
     
     
     
136. PERSOONS L, Vanderlinden E, Vangeel L, Wang X, et al
     Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues.
     Antiviral Res. 2021 Jul 1:105127. doi: 10.1016/j.antiviral.2021.105127.
     PubMed     Abstract available
     
     
     June 2021
137. DO TND, Donckers K, Vangeel L, Chatterjee AK, et al
     A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents.
     Antiviral Res. 2021 Jun 26:105122. doi: 10.1016/j.antiviral.2021.105122.
     PubMed     Abstract available
     
     
     
138. KASHYAP T, Murray J, Walker CJ, Chang H, et al
     Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo.
     Antiviral Res. 2021 Jun 19:105115. doi: 10.1016/j.antiviral.2021.105115.
     PubMed     Abstract available
     
     
     May 2021
139. CHONG Y, Kawai N, Tani N, Bando T, et al
     Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019-2020 influenza season.
     Antiviral Res. 2021;192:105092.
     PubMed     Abstract available
     
     
     April 2021
140. SVYATCHENKO SV, Goncharova NI, Marchenko VY, Kolosova NP, et al
     An influenza A(H5N8) virus isolated during an outbreak at a poultry farm in Russia in 2017 has an N294S substitution in the neuraminidase and shows reduced susceptibility to oseltamivir.
     Antiviral Res. 2021 Apr 29:105079. doi: 10.1016/j.antiviral.2021.105079.
     PubMed     Abstract available
     
     
     
141. ZHAO J, Guo S, Yi D, Li Q, et al
     A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
     Antiviral Res. 2021;190:105078.
     PubMed     Abstract available
     
     
     
142. DU R, Cooper L, Chen Z, Lee H, et al
     Discovery of Chebulagic Acid and Punicalagin as Novel Allosteric Inhibitors of SARS-CoV-2 3CL(pro).
     Antiviral Res. 2021 Apr 16:105075. doi: 10.1016/j.antiviral.2021.105075.
     PubMed     Abstract available
     
     
     March 2021
143. CICCOSANTI F, Di Rienzo M, Romagnoli A, Colavita F, et al
     Proteomic Analysis Identifies the RNA Helicase DDX3X as a Host Target Against SARS-CoV-2 Infection.
     Antiviral Res. 2021 Mar 26:105064. doi: 10.1016/j.antiviral.2021.105064.
     PubMed     Abstract available
     
     
     
144. ROOSENHOFF R, Schutten M, Reed V, Clinch B, et al
     Secondary substitutions in the hemagglutinin and neuraminidase genes associated with neuraminidase inhibitor resistance are rare in the Influenza Resistance Information Study (IRIS).
     Antiviral Res. 2021 Mar 10:105060. doi: 10.1016/j.antiviral.2021.105060.
     PubMed     Abstract available
     
     
     
145. MILANI M, Donalisio M, Bonotto RM, Schneider E, et al
     Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors.
     Antiviral Res. 2021 Mar 10:105055. doi: 10.1016/j.antiviral.2021.105055.
     PubMed     Abstract available
     
     
     February 2021
146. PATEL MC, Chesnokov A, Jones J, Mishin VP, et al
     Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir.
     Antiviral Res. 2021;188:105035.
     PubMed     Abstract available
     
     
     
147. HIDEKAZU OSADA, Chon I, Phyu WW, Wagatsuma K, et al
     Development of cycling probe based real-time PCR methodology for influenza A viruses possessing the PA/I38T amino acid substitution associated with reduced baloxavir susceptibility.
     Antiviral Res. 2021 Feb 9:105036. doi: 10.1016/j.antiviral.2021.105036.
     PubMed     Abstract available
     
     
     
148. MARTIN R, Li J, Parvangada A, Perry J, et al
     Genetic Conservation of SARS-CoV-2 RNA Replication Complex in Globally Circulating Isolates and Recently Emerged Variants from Humans and Minks Suggests Minimal Pre-Existing Resistance to Remdesivir.
     Antiviral Res. 2021 Feb 4:105033. doi: 10.1016/j.antiviral.2021.105033.
     PubMed     Abstract available
     
     
     January 2021
149. LIU C, Boland S, Scholle MD, Bardiot D, et al
     Dual Inhibition of SARS-CoV-2 and Human Rhinovirus with Protease Inhibitors in Clinical Development.
     Antiviral Res. 2021 Jan 27:105020. doi: 10.1016/j.antiviral.2021.105020.
     PubMed     Abstract available
     
     
     
150. ZHU Q, Zhang Y, Wang L, Yao X, et al
     Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.
     Antiviral Res. 2021 Jan 11:105015. doi: 10.1016/j.antiviral.2021.105015.
     PubMed     Abstract available
     
     
     
151. DU R, Cheng H, Cui Q, Peet NP, et al
     Identification of a novel inhibitor targeting influenza A virus group 2 hemagglutinins.
     Antiviral Res. 2021;186:105013.
     PubMed     Abstract available
     
     
     November 2020
152. SVENNINGSEN EB, Thyrsted J, Blay-Cadanet J, Liu H, et al
     Ionophore antibiotic X-206 is a potent inhibitor of SARS-CoV-2 infection in vitro.
     Antiviral Res. 2020 Nov 25:104988. doi: 10.1016/j.antiviral.2020.104988.
     PubMed     Abstract available
     
     
     
153. ZHANG Y, Song W, Chen S, Yuan Z, et al
     A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2.
     Antiviral Res. 2020 Nov 17:104974. doi: 10.1016/j.antiviral.2020.104974.
     PubMed     Abstract available
     
     
     
154. HEJDANEK J, Radilova K, Pachl P, Hodek J, et al
     Structural characterization of the interaction between the C-terminal domain of the influenza polymerase PA subunit and an optimized small peptide inhibitor.
     Antiviral Res. 2020 Nov 6:104971. doi: 10.1016/j.antiviral.2020.104971.
     PubMed     Abstract available
     
     
     
155. ZARAKET H, Hurt AC, Clinch B, Barr I, et al
     Burden of influenza B virus infection and considerations for clinical management.
     Antiviral Res. 2020 Nov 4:104970. doi: 10.1016/j.antiviral.2020.104970.
     PubMed     Abstract available
     
     
     October 2020
156. CHOI SW, Shin JS, Park SJ, Jung E, et al
     Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
     Antiviral Res. 2020 Oct 19:104955. doi: 10.1016/j.antiviral.2020.104955.
     PubMed     Abstract available
     
     
     September 2020
157. SAITO R, Osada H, Wagatsuma K, Chon I, et al
     Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions.
     Antiviral Res. 2020;183:104951.
     PubMed     Abstract available
     
     
     
158. THEERAWATANASIRIKUL S, Kuo CJ, Phecharat N, Chootip J, et al
     Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
     Antiviral Res. 2020 Sep 7:104927. doi: 10.1016/j.antiviral.2020.104927.
     PubMed     Abstract available
     
     
     
159. GURARD-LEVIN ZA, Liu C, Jekle A, Jaisinghani R, et al
     Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.
     Antiviral Res. 2020 Sep 4:104924. doi: 10.1016/j.antiviral.2020.104924.
     PubMed     Abstract available
     
     
     August 2020
160. KONKOLOVA E, Dejmek M, Hrebabecky H, Sala M, et al
     Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses.
     Antiviral Res. 2020 Aug 4:104899. doi: 10.1016/j.antiviral.2020.104899.
     PubMed     Abstract available
     
     
     July 2020
161. OKAMOTO M, Toyama M, Baba M
     The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro.
     Antiviral Res. 2020 Jul 30:104902. doi: 10.1016/j.antiviral.2020.104902.
     PubMed     Abstract available
     
     
     
162. PAN X, Zhou P, Fan T, Wu Y, et al
     Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro.
     Antiviral Res. 2020 Jul 10:104868. doi: 10.1016/j.antiviral.2020.104868.
     PubMed     Abstract available
     
     
     
163. SALINAS FM, Nebreda AD, Vazquez L, Gentilini MV, et al
     Imiquimod suppresses respiratory syncytial virus (RSV) replication via PKA pathway and reduces RSV induced-inflammation and viral load in mice lungs.
     Antiviral Res. 2020;179:104817.
     PubMed     Abstract available
     
     
     May 2020
164. BLOCKUS S, Sake SM, Wetzke M, Grethe C, et al
     Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry.
     Antiviral Res. 2020;177:104774.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: